Cancer claims and specialty drugs drive stop-loss cost surge: QBE
The annual report, which draws on QBE’s proprietary claims data, found that neoplasms account for 36% of all stop-loss claim…
Blog
The annual report, which draws on QBE’s proprietary claims data, found that neoplasms account for 36% of all stop-loss claim…
Most employers and their insurance resources are aware of the abusive cost structures associated with prescription compound topical drugs/creams being…
The Trump administration took steps on Monday that appear likely to result in new tariffs on semiconductors and pharmaceutical products,…
Among the 167 million people with employer-sponsored insurance in 2022, 3.4 million used at least one of the first 10…
In his first week in office, President Trump tried to browbeat governments across the world into ending the flow of…
More than two in five (42%) or 57.4 million adults under 65 with private insurance could be eligible under clinical…